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Multicomponent DNA vaccines were used to elicit immune responses, which can impact viral challenge in three separate
rhesus macaque models. Eight rhesus macaques were immunized with DNA vaccines for HIV env/rev and SIV gag/pol and
were challenged intravenously with 10 animal infective doses (AID50) of cell-free SHIV IIIB. Three of eight immunized rhesus
macaques were protected, exhibiting no detectable virus. Animals protected from nonpathogenic SHIVIIIB challenge were
rested for extended periods of time and were rechallenged first with pathogenic SIVmac239 and subsequently with pathogenic
SHIV89.6P viruses. Following the pathogenic challenges, all three vaccinated animals were negative for viral coculture and
antigenemia and were negative by PCR. In contrast, the control animals exhibited antigenemia by 2 weeks postchallenge and
exhibited greater than 10 logs of virus/106 cells in limiting dilution coculture. The control animals exhibited CD4 cell loss and
developed SIV-related wasting with high viral burden and subsequently failed to thrive. Vaccinated animals remained
virus-negative and were protected from the viral load, CD4 loss, disease, and death. We observed strong Th1-type cellular
immune responses in the protected macaques throughout the study, suggesting their important roles in protection. These
studies support the finding that multicomponent DNA vaccines can directly impact viral replication and disease in a highly
pathogenic challenge system, thus potentially broadening our strategies against HIV. © 2001 Academic Pressa
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Since its initial development in the early 1990s, DNA
vaccine strategy has become one of the key technolo-
gies in vaccine development. Countless academic and
government laboratories have DNA vaccine programs,
which target diseases ranging from TB to HIV as well as
for the immunotherapy of various types of cancer (Don-
nelly et al., 1997; Weiner and Kennedy, 1999). In addition,
several biotechnology companies as well as some large
pharmaceutical companies have active DNA vaccine
programs. Even though the early clinical results show
the glimpse of potential utility of this strategy, further
testing in animal models and humans is important for the
development of clinically relevant vaccines (Boyer et al.,
2000; Wang et al., 1998).
Primates represent relevant models for HIV vaccine
evaluation (Hulskotte et al., 1998; Marx et al., 1993). For
HIV vaccine studies, these primate challenge models
can be segregated into three categories: the HIV chal-
lenge model in chimpanzees and the SIV and chimeric
SIV/HIV-1 (SHIV-1) challenge models in macaques (Lu-
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204ciw et al., 1995; Ranjbar et al., 1997). Chimpanzees can
be infected by HIV isolates from humans; however, they
rarely develop disease and are limited in quantity—a
problem for vaccine testing. In contrast, the SIV chal-
lenge model uses an SIV virus, which replicates to high
levels in rhesus macaques and causes a HIV-like dis-
ease in this plentiful species. In an effort to test HIV
envelope immunogens in an animal model, the SHIV
viruses were constructed by replacing SIV envelope
genes with specific HIV-1 envelope genes (Schultz and
Hu, 1993). SHIV viruses replicate in macaques and rep-
resent an infectious challenge model for HIV-1 envelope-
based vaccines. Furthermore, certain SHIV strains such
as SHIV 89.6P are pathogenic.
In this study, we examined the effect of multicompo-
nent DNA vaccine immunization on viral challenges in
rhesus macaques. The animals were immunized with a
multicomponent DNA vaccine cocktail consisting of DNA
plasmids expressing HIV envMN and SIV gag/pol genes
s well as those expressing cytokine genes. We ob-
erved that three of eight rhesus macaques immunized
ith multicomponent DNA vaccines were protected from
subsequent intravenous (iv) challenge with SHIVIIIB
irus and exhibited no detectable virus in the limiting
ilution coculture assay. Animals protected from non-
athogenic SHIVIIIB challenge were rested for long pe-
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205IMMUNODEFICIENCY VIRUS CHALLENGES IN RHESUS MACAQUESriods of time and were rechallenged with pathogenic
SIVmac239 and SHIV89.6P viruses. Interestingly, all three
rhesus macaques were protected from the viral load,
CD4 loss, disease, and death in these multiple patho-
genic challenge models. These results suggest potential
utility of multicomponent DNA vaccine strategy.
RESULTS
Analysis of DNA immunization in a SHIV IIIB
challenge
Eight rhesus macaques were immunized with multi-
component DNA vaccines and two rhesus macaques
were immunized with control plasmids as described un-
der Materials and Methods. The potential effects of cy-
tokine coimmunization on DNA vaccine-induced immune
responses in rhesus macaques have been previously
published (Kim et al., 2000, 2001). Due to the small
number of animals for each cytokine group, all DNA
vaccine-immunized rhesus macaques (eight total) were
pooled as one group prior to the SHIVIIIB challenge.
At week 53 (4 weeks after the last immunization), eight
rhesus macaques immunized with multicomponent DNA
vaccine cocktail as well as two control macaques were
challenged by iv route with 10 animal infective doses
(AID50) of cell-free SHIV IIIB. Animals were then bled at 2,
, and 4 weeks after the challenge and were assessed
or protection from infection using a standard sensitive
imiting dilution coculture analysis (Wyand et al., 1996).
s expected, both control macaques were infected
ithin 2 weeks of viral challenge (Fig. 1). In contrast, we
bserved that three of eight immunized animals were
ble to prevent viral antigenemia due to iv challenge and
xhibited no detectable virus in the limiting dilution co-
ulture assay.
Based on the humoral immune responses measured
n the protected and unprotected macaques, neutralizing
ntibody responses do not appear to correlate with con-
rol of viral replication and infection in this study (Kim et
l., 2000). Comparison of cell-mediated immune re-
ponses (CMI) in protected and nonprotected rhesus
acaques suggests the importance of CMI for protection
Table 1). Based on these results, protection seemed to
avor stronger CTL and/or stronger and more frequent
PAs, particularly to gag. To further characterize the
ellular immune responses, we also analyzed the cyto-
ine expression profiles from individual animal’s stimu-
ated T cells immediately prior to challenge at week 53.
ytokines play a key role in directing and targeting im-
une cells during the development of the immune re-
ponse. For instance, IFN-g is produced by Th1-type
CD41 and CD81 T cells and is intricately involved in the
regulation or development of antiviral T-cell-mediated
immune responses (Clerici and Shearer, 1993; Rosen-
berg et al., 1997). In contrast, IL-10 is produced by many
cell types, including putative Th2 lymphocytes, and hasbeen shown to be a potent Th2-type cytokine (Fiorentino
et al., 1989). Thus, analysis of these cytokines secreted
by stimulated T cells may be important in elucidating the
extent of cell-mediated responses following immuniza-
tion (Lekutis et al., 1997). As shown in Table 2, the
stimulated T cells from the protected rhesus macaques
produced significantly higher levels of IFN-g than the
unprotected animals (both control and immunized). On
the other hand, the levels of IL-10 produced by the
protected and the unprotected groups were similar.
Accordingly, several reports illustrate that chemokines
can also modulate immune responses or can have a role
in viral infection (Heeny et al., 1997; Lehner et al., 1996).
e examined the expression profiles of b-chemokines
(MIP-1a, MIP-1b, RANTES, and MCP-1) from immunized
nimals at week 53, just prior to challenge. The b-che-
mokines MIP-1a, MIP-1b, and RANTES are the major HIV
suppressive factors produced by CD81 T cells for mac-
ophage-tropic, but not T-cell-tropic, viruses (Cocchi et
l., 1995; Doranz et al., 1996; Dragic et al., 1996). Although
CP-1 has not been identified as one of the HIV sup-
ressive factors, it has been shown to play a role in
ellular immune expansion in the periphery (Kim et al.,
998a). The stimulated T cells from the protected rhesus
acaques produced significantly higher levels of MIP-1b
and RANTES than the unprotected animals (with P val-
es of 0.05 and 0.02, respectively) (Table 2). In contrast,
he levels of MIP-1a and MCP-1 production by the two
groups were not significantly different. Therefore, by four
criteria—LPA responses, CTL responses at time of chal-
lenge, expression of IFN-g, and expression of chemo-
ines, RANTES and MIP-1b—a cellular bias appears to
favor protection in this SHIV IIIB challenge study.
Protection from a pathogenic SIVmac239 challenge
SIV challenge models in macaques represent relevant
odel systems for studying the immunology and disease
athogenesis from immunodeficiency virus. In addition
o the test against infectious virus afforded by the SHIV
IIB challenge, pathogenic SIV challenge allows the eval-
ation of vaccination strategy against disease pathogen-
sis. It has been, in general, more difficult to protect
accinated primates against pathogenic SIV challenge
odels.
A study by Robinson et al. demonstrated that a prime
oost approach supported the finding that intradermal
NA vaccination followed by pox viral booster could
ontrol pathogenic infection in most vaccinated animals
Robinson et al., 1999). We next sought to confirm and
xtend this finding in this DNA-based study. The three
rotected monkeys from SHIV IIIB challenge were rested
or 6 months. Then, these animals were boosted with 1
g of SIV env and gag/pol DNA constructs at weeks 81
nd 85. Subsequently, we examined the level of antigen-
pecific lymphoproliferative responses against SIV p27
s206 KIM ET AL.FIG. 1. Viral load following challenge with cell-free SHIV IIIB at week 53. The macaques were challenged by iv route with 10 animal infective doses
(AID50) of cell-free SHIV IIIB at week 53. Animals were then bled at 2, 3, and 4 weeks after the challenge and analyzed for virus detection using a
ensitive limiting dilution coculture analysis.
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207IMMUNODEFICIENCY VIRUS CHALLENGES IN RHESUS MACAQUESgag and gp130 env proteins. As shown in Fig. 2, after two
booster immunizations (at weeks 81 and 85), all three
immunized animals had positive LPA responses.
At week 89, these animals as well as a control ma-
caque were challenged by iv route with 10 AID50 of
pathogenic SIVmac239. The animals were bled 2 and 4
weeks prior to challenge and at several time points
following challenge. The infection with SIVmac239 was as-
essed for plasma antigenemia and by PCR analysis.
sing a plasma antigenemia assay, we observed a high
imiting dilution coculture level of p27 antigen in the
lasma of the control animal at 2 weeks postchallenge,
hile we did not detect any p27 antigen in the three
accine recipients (data not shown). These results were
ubstantiated by the limiting dilution coculture and PCR
nalyses. The control animal was infected, as virus was
eadily detected within 1 week of challenge. The viral
oad remained high throughout the analysis period
greater than 10 logs of virus/106 cells). In contrast, 100%
of the immunized macaques showed a complete ab-
TABLE 1
Cellular Responses in Protected vs Infected Rhesus Macaques
Protected
Antigen-specific LPA responses (SI . 4)
aEnv protein aGag protein Total
MK1 2/4 4/7 6/11
MK3 2/4 4/7 6/11
MK5 1/4 2/7 3/11
5/12 10/21 15/33 (45%)
Infected
Antigen-specific LPA responses (SI . 4)
aEnv protein aGag protein Total
MK2 2/4 1/7 3/11
MK4 1/4 1/7 2/11
MK6 3/4 1/7 4/11
MK7 0/4 2/7 2/11
MK8 1/4 3/7 4/11
7/20 8/35 15/55 (27%)
No. of macaques with 1 CTL (.10%)
at time of challenge (at week 53)
Protected 2/3 (67%)
Infected 2/6 (33%)
T
Variant Levels of Cytokine and Chemokine
IFN-g IL-10 M
Protected 662 (620) 300 (64) 470
Not protected 384 (6147) 286 (635) 590
Student’s t test (P value) 0.01 0.53sence of viral load when assayed by the limiting cocul-
ture method through 20 weeks postchallenge (Fig. 3A).
The three animals were also virus-negative by PCR anal-
ysis.
Moreover, as early as 14 weeks post-SIV challenge,
the CD41 and CDw291 T cell subsets in the control
nimal began to decline while the uninfected animals
aintained normal levels of CD4 and CDw29 cell per-
entages (Fig. 3B). By 18 weeks, the infected control
nimal exhibited several adverse clinical symptoms such
s weight loss, lethargy, ruffled fur, and diarrhea, consis-
ent with SIV-induced disease. In fact, the health of the
ontrol animal continually deteriorated and the animal
as euthanized by week 30 postchallenge. All vacci-
ated animals have remained healthy.
Since the design of the rechallenge study did not
learly demonstrate that the protection from SIVmac239
challenge is entirely due to DNA vaccines tested or due
to DNA as prime and SHIVIIIB challenge as boost, we
directly examined whether prior SHIVIIIB infection could
provide protection from SIVmac239 challenge. A new set of
eight rhesus macaques previously infected with SHIVIIIB
virus was rested for 40 weeks after infection. We then
rechallenged these animals as well as two naive control
macaques with 10 AID50 of pathogenic SIVmac239. As
hown in Fig. 4, two naive control macaques were readily
nfected with SIVmac239 virus. We also observed that prior
nfection with SHIVIIIB virus did provide partial modula-
ion of protection, as the SHIVIIIB infection lessened the
iral load levels. On the other hand, prior infection with
HIVIIIB did not provide similar levels of protective im-
unity observed in vaccine-immunized rhesus ma-
aques in Fig. 3, as only one of eight SHIVIIIB-infected
acaques (12.5%) was protected from infection with
IVmac239 virus.
rotection from a pathogenic SHIV89.6P challenge
In order to further test this vaccination strategy against
nother pathogenic viral challenge, we sought to evalu-
te the effects of DNA vaccines against the severely
athogenic SHIV89.6P challenge model. A chimeric
HIV89.6P virus is a highly pathogenic and virulent virus
enerated by in vivo passages of SHIV89.6 virus in rhe-
us macaques (Karlsson et al., 1997; Reimann et al.,
996). SHIV89.6 virus is composed of SIVmac239 ex-
ressing HIV-1 tat, rev, vpu, and env of a cytopathic,
ction by Protected and Infected Animals
MIP-1b RANTES MCP-1
) 12,642 (63,512) 16,222 (62,177) 6825 (62,466)
31) 4988 (62,091) 5851 (62,678) 3633 (61,392)
0.05 0.02 0.14Produ
IP-1a
6 (6752
5 (61,3
0.25
FIG. 2. Envelope-specific (A) and gag-specific (B) LPA responses following immunization and prior to pathogenic SIVmac239 challenge.
li
209IMMUNODEFICIENCY VIRUS CHALLENGES IN RHESUS MACAQUESmacrophage-tropic clone of a patient isolate of HIV-1
(89.6) (Reimann et al., 1996). SHIV89.6P virus has been
shown to induce rapid CD41 lymphocyte depletion,
AIDS-like illness, and rapid disease in rhesus macaques
(Reimann et al., 1996, 1999).
FIG. 3. (A) Viral load following challenge with pathogenic SIVmac239. Th
v route with 10 AID50 of pathogenic SIVmac239 at week 89. Following the
and after the challenge and were analyzed for virus detection using a lim
in the plasma using the branched DNA assay before and after virus cha
challenge. Fourteen weeks following SIV challenge (week 103), wh
T-lymphocyte subsets.The three protected monkeys from the SHIV IIIB and
SIVmac239 challenges were rested for one additional year
following the SIVmac239 challenge. These animals were
boosted with 1 mg of HIV envMN, a heterogeneous enve-
ope, and SIV gag/pol DNA constructs at study weeks
ccinated animals as well as one control macaque were challenged by
ge with SIVmac239, the animals were bled at several time points before
ilution coculture analysis. The figure also shows the levels of SIV RNA
(B) Maintenance of CD41, CD81, and CDw291 cells following SIVmac239
od samples were collected from the macaques and analyzed forree va
challen
iting d
llenge.
ole blo
r
g
g
s
(
i
p
W
a
s
u
m
p
m
f
s
W
a
r
t
s
t
T
a
c
F
u
210 KIM ET AL.145 and 149. Subsequently, we analyzed the level of
antigen-specific LPA responses against SIV p27 gag and
HIV gp120 envMN proteins. Throughout the analysis pe-
iod, all three immunized animals showed potent anti-
en-specific LPA responses to SIV p27 gag and HIV
p120 envMN proteins, while the control animal did not
how any reactivity against the gag and env antigens
Fig. 5). It is also important to note that the animals were
mmunized with DNA construct expressing HIV envelope
rotein from the MN strain and not from the 89.6P strain.
e also analyzed the IFN-g expression profiles from the
nimals immediately prior to challenge at week 153. As
hown in Fig. 6C, we observed higher levels of IFN-g
from the immunized rhesus macaques versus the control
animal. These results are consistent with the results
shown in Table 2, where the stimulated T cells from the
rhesus macaques protected from SHIVIIIB produced
higher levels of IFN-g than the control or immunized but
nprotected animals.
At week 153, these animals as well as a control naive
acaque were challenged by the iv route with 10 AID50 of
athogenic SHIV89.6P. Blood was drawn from the ani-
als several weeks prior to challenge and at time points
ollowing challenge. Infection by SHIV89.6P was as-
essed by limiting dilution coculture and PCR analysis.
e observed a high level of viral infection in the control
nimal within 1 week of challenge, and the viral load
FIG. 4. Protective effects of SHIVIIIB infection on viral challenge with
rested for 40 weeks. These macaques as well as two naive control m
ollowing the challenge with SIVmac239, the animals were bled at severa
sing a limiting-dilution coculture analysis.emained high throughout the analysis period. In con-
rast, 100% of the immunized macaques showed ab-
ence of viral load when assayed by the limiting cocul-
ure method through 6 weeks postchallenge (Fig. 6A).
he immunized animals were also virus-negative by PCR
nalysis.
T cell subsets were also studied. Compared to the
ontrol animal from the SIVmac239 challenge, the control
animal from the SHIV89.6P challenge had its CD41 and
CDw291 T cell subsets decline much more rapidly (Fig.
6B). As early as 2 weeks post-SHIV89.6P challenge, the
CD41 and CDw291 T cell subsets on the control animal
began to collapse, while the immunized and uninfected
animals maintained normal levels. The infected control
animal exhibited severe adverse clinical symptoms such
that the animal had to be euthanized by week 24 post-
challenge. All vaccinated animals have remained healthy
and viral negative and were protected from T cell as-
pects of viral pathogenesis during the duration of obser-
vation (.1 year postchallenge) (data not shown).
DISCUSSION
One of the hallmarks of HIV-1 disease progression is
the loss of cellular immune function, and the presence of
strong cellular responses in some instances can corre-
late with control of viral replication (Kim and Weiner,
enic SIVmac239. Eight rhesus macaques infected with SHIVIIIB virus were
es were challenged by iv route with 10 AID50 of pathogenic SIVmac239.
points before and after the challenge and analyzed for virus detectionpathog
acaqu
l time
FIG. 5. Envelope-specific (A) and gag-specific (B) LPA responses following immunization and prior to pathogenic SHIV89.6P challenge.
212 KIM ET AL.
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213IMMUNODEFICIENCY VIRUS CHALLENGES IN RHESUS MACAQUES1997; Letvin, 1998). In cases of acute HIV-1 infection
studied by several investigators, viral clearance was
associated with specific CTL activity in each case (Bor-
row et al., 1994; Koup et al., 1994). In addition, a subset (7
of 20) of occupationally exposed health-care workers
who were not infected possessed transient HIV-1 spe-
cific CTL response (Pinto et al., 1995). HIV-1-specific
CTLs were also found in a number of chronically ex-
posed sex workers in Gambia who continue to resist
infection with HIV-1 (Rowland-Jones et al., 1995). In spite
of these studies supporting the role of neutralizing anti-
bodies and CTLs in conferring immunity to infection,
some vaccinated primates exhibiting both neutralizing
antibody and CTL responses were not protected from
subsequent viral challenge in the pathogenic SIV model
(Hulskotte et al., 1995). Recently, the important role of
D4 helper responses in the anti-HIV immune response
as been highlighted (Rosenberg et al., 1997). Such re-
ponses likely have importance for both humoral and
D81 effector responses.
Overall, the present studies provide some insights into
he importance of T-cell-mediated immune responses.
eutralizing antibodies were not detected at the time of
HIVIIIB challenge (Kim et al., 2000) and the envelope
onstructs used in the first and third challenges were not
atched. Here, the results from the three SHIV and SIV
hallenge model studies support the finding that CMI
esponses, especially the Th1-type T cell responses,
ight be important for protection against infectious and
athogenic challenges. In these studies, the protective
ffects seemed to suggest the presence and the strength
f antigen-specific LPA responses. Furthermore, these
PA responses had Th1 phenotype, with potent induction
f IFN-g. For instance, the level of IFN-g detected in
ymphocytes from the macaques protected from the
HIVIIIB challenge was greater than those of the unpro-
ected control animals or the unprotected vaccinated
nimals (Table 2). Similarly, the macaques protected
rom the SHIV89.6P challenge had high levels of T-cell-
roduced IFN-g (Fig. 6C). The data also support further
nvestigation of the importance of T-cell-produced che-
okines. The protected rhesus macaques also produced
ignificantly higher levels of MIP-1b (P value 5 0.05) and
RANTES (P value 5 0.02) than the unprotected animals
Table 2). These results support the finding that induction
f b-chemokines through an immunization strategy
should be further studied in relation to protection (Heeny
et al., 1997; Lehner et al., 1996).
Accordingly, one possible correlate appears to be driv-
FIG. 6. (A) Viral load following challenge with pathogenic SHIV89.6P
by iv route with 10 AID50 of pathogenic SHIV89.6P at week 153. Followin
before and after the challenge and were analyzed for virus detection us
in the plasma using the branched DNA assay before and after virus
HIV89.6P challenge. The animals were bled at several time points bef
-lymphocyte subsets. (C) Blood samples were drawn from animals im
itro for 72 h with SIV gag p27 protein (at 5 mg/ml). Expression of IFNing responses toward a Th1 phenotype, a theory that had
been under investigation previously (Clerici et al., 1993).
This current study tested a low-dose immunization pro-
tocol compared to doses in other studies (Letvin et al.,
1997; Lu et al., 1996; Putkonen et al., 1998). It will be
important to evaluate more aggressive doses and reex-
amine protection in a larger number of animals. The
protective results against both SHIV and SIV challenges
strongly suggest an important role for gag/pol immuno-
gens in generating protective responses in these models
and the development of vaccines in humans.
As it has already been clearly established that env
protein vaccines can protect in SHIVIIIB model in a
type-specific fashion, these results support the finding
that multiple immune mechanisms can be important and
together may broaden protection (Letvin et al., 1997). In
the present trials this appears not to be the case as no
clear induction of type-specific neutralizing antibodies
were observed in protected animals in any of the studies.
Furthermore, in the latter challenge, MN env-immunized
animals were protected from iv challenge with SHIV
89.6P virus, further distinguishing the protection ob-
served here from a type-specific antibody response. In
this pilot study, we observed that the animals protected
in the first study were protected in subsequent chal-
lenges with SIVmac239 and SHIV89.6P. Animals were pro-
tected based on a lack of antigenemia, viral detection,
and most importantly, disease and death in all immu-
nized macaques, strongly supporting additional studies
in this area. The results are important as they support the
finding that cellular immune responses can play a role in
this important outcome. However, these studies only
support and do not clearly establish which cellular arms
are responsible for viral control in this model.
It was not clear whether the protection from SIVmac239
challenge is entirely due to DNA vaccines tested or due
to DNA as prime and SHIVIIIB challenge as boost. More
specifically, it is important to consider the role of SHIVIIIB
challenge as a boosting agent for gag-specific cellular
responses in this study. It has been previously reported
that prior infection with a SHIV HXBc2 virus does not
provide protective immunity against a pathogenic SIV
challenge (Letvin et al., 1995). In this regard, we directly
xamined whether prior SHIVIIIB infection could provide
rotection from SIVmac239 challenge. Eight rhesus ma-
caques infected with SHIVIIIB virus were rested for 40
weeks. We then rechallenged these animals as well as
two naive control macaques with 10 AID50 of pathogenic
SIVmac239. As shown in Fig. 4, two naive control macaques
vaccinated animals as well as one control macaque were challenged
hallenge with SHIV89.6P, the animals were bled at several time points
ilution coculture analysis. The figure also shows the levels of SIV RNA
nge. (B) Maintenance of CD41, CD81, and CDw291 cells following
after the challenge and their whole blood samples were analyzed for
ely prior to challenge at week 153. Purified PBMC were stimulated in
stimulated T cells were analyzed by ELISA.. Three
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214 KIM ET AL.were readily infected with SIVmac239 virus. We observed
that prior infection with SHIVIIIB virus did not provide
similar levels of protective immunity observed in Figs. 3
and 6, as only one of eight SHIVIIIB-infected macaques
(12.5%) was protected from infection with SIVmac239 virus.
Previous infection did seem to provide partial modulation
of protection as the SHIVIIIB infection lessened the viral
load levels (Fig. 4).
It is also interesting that studies from Rupprecht et al.
support the finding that a threshold of replication is
required to engender subsequent protection (Ruprecht et
al., 1996). This was not the case in our studies, which
resulted in protection from SIVmac239 and SHIV89.6P chal-
enges, as no clear levels of replication were observed.
A study by Robinson et al. is important in this regard
sing a prime (ID DNA) boost (fowlpox) approach fol-
owed up by nonpathogenic SHIV and then subsequent
athogenic SHIV challenge (Robinson et al., 1999). These
uthors also found little evidence of neutralizing antibody
esponse-mediated protection. The results of our study
re highly consistent with these concepts. In addition, it
as observed that cellular responses can have a direct
rotective role against pathogenic and nonpathogenic
hallenges. Importantly, new insight provided by these
hallenges extends these properties, perhaps under cer-
ain conditions, to im DNA vaccination in the absence of
ive vector boosting. These studies are also supported by
he recent work of Barouch et al. (2000). In this study,
lasmid vaccines encoding env and gag from 89.6P virus
nd IL-2 Ig either as protein or as plasmid did not prevent
nfection but prevented significant loss of CD4 T cells
nd resulted in animals that could control viral load.
hese studies, however, used unmatched envs for the
hallenge, so the questions of humoral responses in
rotection were unresolved. The observation in two sep-
rate studies that protection in nonpathogenic SHIV
odel systems results in successes with high frequency
n pathogenic challenges should not go unappreciated.
Additional studies are warranted to resolve these is-
ues. However, these results demonstrate that protec-
ion from pathogenic challenge can be achieved in the
bsence of high viral replication that reaches a threshold
evel of replication for effective vaccination (Figs. 3A and
B), a concern for vaccine safety (Ruprecht et al., 1996).
urthermore, significant control over viral set point and
revention of CD4 loss, disease, and death (Figs. 3B and
B) can be achieved in multiple nonhuman primate chal-
enge models of HIV through such an immunization ap-
roach. This is encouraging for further development of a
rophylactic vaccine for HIV-1, as it implies that viral set
oint in this model can be controlled with a combination
f vaccination techniques which are conceptually simple
o design and likely to be safe to administer. However,
ltimately, the use of primate models to predict effective-
ess in human population is of considerable debate.MATERIALS AND METHODS
NA plasmids
DNA vaccine constructs expressing HIV-1 envelope
rotein (pCEnv) and those expressing SIV gag/pol pro-
ein (pCSGag/Pol) were prepared as previously de-
cribed (Wang et al., 1995). The cytokine genes were
cloned into the pCDNA3 expression vector (Invitrogen,
Inc., San Diego, CA) as previously described (Kim et al.,
1998b).
Reagents
Recombinant HIV-1 gp120 and SIV p27 proteins were
obtained from ImmunoDiagnostics, Inc. (Bedford, MA).
Animals
Rhesus macaques (Macaca mulatta) were individually
housed at the Primedica Mason Labs (Worcester, MA).
All animal care and use procedures conformed to the
revised Public Health Service Policy on Humane Care
and Use of Laboratory Animals. Animals were anesthe-
tized with ketamine HCl for all technical procedures.
Macaque immunization and challenge virus
inoculation
Macaques were immunized intramuscularly (im) in the
quadriceps with DNA preparations formulated in phos-
phate-buffered saline (PBS) and 0.25% bupivacaine–HCl
(Sigma, St. Louis, MO) (Kim et al., 1997, 1998b) on multi-
ple occasions. Initially, five groups of two rhesus ma-
caques each were immunized with various DNA vaccine
constructs. The first group (MK1 and MK2) was immu-
nized with HIV envMN/rev (pCEnv) and SIV gag/pol (pCS-
ag/pol) constructs along with a control vector pCDNA3.
he second group (MK3 and MK4) was immunized with
CEnv 1 pCSGag/pol 1 IL-2 constructs. The third (MK5
and MK6) and fourth groups (MK7 and MK8) were immu-
nized with pCEnv 1 pCSGag/pol 1 IL-4 and pCEnv 1
pCSGag/pol 1 IFN-g, respectively. These macaques
were immunized with 200 mg of each DNA at weeks 0, 6,
nd 12 and boosted with 500 mg of each DNA at weeks
28 and 49. These constructs were mixed prior to injection
into the quadriceps muscle. The control group was im-
munized with 500 mg of pCDNA3 at weeks 28 and 49. At
eek 53 of the study, all macaques were challenged
ntravenously (iv) with 10 AID50 of SHIV IIIB (provided by
Yichen Lu, Virus Research Institute). At week 89, a sub-
set of animals that were negative for virus recovery
following SHIV challenge were challenged iv with 10
AID50 of SIVmac239 (provided by Ronald C. Desrosiers, New
ngland Regional Primate Research Center). Naive con-
rol animals were included at each challenge time point.
t week 153, three immunized macaques and one con-
rol macaque were challenged iv with 10 AID50 of patho-
enic SHIV89.6P (provided by Norman Letvin, Harvard
edical School).
o
p
P
t
t
P
d
(
P
c
v
w
t
T
215IMMUNODEFICIENCY VIRUS CHALLENGES IN RHESUS MACAQUESLymphoproliferative assay
Peripheral blood lymphocytes were prepared as pre-
viously described (Boyer et al., 1997). The isolated cell
suspensions were resuspended to a concentration of
5 3 105 cells/ml in a medium consisting of RPMI 1640
(Gibco-BRL, Grand Island, NY) with 10% fetal calf serum
(Gibco-BRL). A 100-ml aliquot containing 5 3 105 cells
was immediately added to each well of a 96-well micro-
titer round-bottom plate. Recombinant p27 or gp120 pro-
tein at final concentrations of 5 and 1 mg/ml were added
to wells in triplicate. The cells were incubated at 37°C in
5% CO2 for 3 days. One microcurie of tritiated thymidine
was added to each well and the cells were incubated for
12–18 h at 37°C. The plates were harvested and the
amount of incorporated tritiated thymidine was mea-
sured in a Beta Plate reader (Wallac, Turku, Finland).
Stimulation Index was determined from the formula
Stimulation Index (SI)
5 (experimental count/spontaneous count).
Spontaneous count wells (media only) include 10% fetal
calf serum. To ensure that cells were healthy, con-
canavalin A (Sigma) was used as a polyclonal stimulator
positive control.
Cytotoxic T-lymphocyte assay
A standard 5-h 51Cr-release CTL assay was performed
n PBMCs from the inoculated and control macaques as
reviously described (Boyer et al., 1997). Cells for in vitro
stimulation of T cells were prepared by infecting autolo-
gously transformed B-lymphoblastoid cell lines (LCLs)
with a recombinant vaccinia virus which expressed
SIVmac239 env/gag/pol proteins (Therion, Boston, MA).
rior to use the infected cells were fixed with 0.1% glu-
araldehyde and blocked with a 0.1 mM glutamine solu-
ion. The fixed cells were incubated with the isolated
BMCs (effectors) for stimulation in CTL stimulator me-
ium (RPMI 1640 (Gibco-BRL), 10% fetal calf serum
Gibco-BRL), and recombinant IL-2 (40 U/ml) (Intergen,
urchase, NY)) for 21 days. The LCLs infected with spe-
ific recombinant vaccinia virus or control recombinant
accinia virus expressing b-galactosidase (vSC8) were
also used as target cells. Cells incubated with the control
vaccinia were used as targets to provide background
levels of lysis.
Cytokine and chemokine expression analysis
Supernatants from effectors stimulated for CTL assay
(see above) were collected after specific stimulation and
were tested for cytokine profile using ELISA kits for IFN-g
and IL-10 (Biosource International, Inc., Camarillo, CA).
Similarly, expression of MIP-1a, MIP-1b, RANTES, and
MCP-1 was analyzed using ELISA kits (Intergen). For
each sample at each time point, 100 ml of supernatant
as tested in triplicate wells. Each well value was usedo derive the average and the standard deviation values.
he P values were calculated using Student’s t test.
Cell-associated virus load by limiting dilution
coculture
Viral load was determined by limiting dilution cocul-
ture of isolated PBMC with CEMx174 target cells using a
method previously described (Wyand et al., 1996). Twelve
serial 1:3 dilutions of PBMC, beginning with 106 cells,
were cocultured in duplicate with 105 CEMx174 cells per
well in 24-well plates. Supernatant samples were col-
lected after 21 days of culture and stored frozen at
270°C until analysis for p27 antigen with the Coulter p27
antigen assay kit.
Plasma RNA
Plasma samples from whole blood collected in sodium
citrate were analyzed for SIV RNA copies per milliliter
using the branched DNA assay (bDNA) developed by
Chiron Corp., Emeryville, CA.
Flow cytometry
Whole blood collected in EDTA was analyzed for lym-
phocyte subsets CD4 (Anti-Leu 3a (Becton–Dickinson)),
CD8 (Anti-Leu 2a (Becton–Dickinson)), and CDw29 (4B4)
(Coulter Immunology) after red blood cell lysis using
methods previously described (Wyand et al., 1996).
Briefly, antibody (volume dependent upon antibody) was
added to 100 mL of whole blood and incubated for 10 min
in the dark. Lysing solution (Becton–Dickinson) was
added and the samples were incubated for 10 min at
room temperature. Stained cells were fixed with 0.5%
paraformaldehyde. Samples were analyzed on a Becton–
Dickinson FACScan cytometer.
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